IMAGENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Imagent, and what generic alternatives are available?
Imagent is a drug marketed by Vesselon Spv Llc and Alliance Pharm and is included in two NDAs.
The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IMAGENT?
- What are the global sales for IMAGENT?
- What is Average Wholesale Price for IMAGENT?
Summary for IMAGENT
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 96 |
| Patent Applications: | 3,810 |
| DailyMed Link: | IMAGENT at DailyMed |
US Patents and Regulatory Information for IMAGENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vesselon Spv Llc | IMAGENT | dimyristoyl lecithin; perflexane | INJECTABLE;INTRAVENOUS | 021191-001 | May 31, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alliance Pharm | IMAGENT | perflubron | LIQUID;ORAL | 020091-001 | Aug 13, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IMAGENT
International Patents for IMAGENT
See the table below for patents covering IMAGENT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1182373 | ⤷ Sign Up | |
| Germany | 69434119 | ⤷ Sign Up | |
| Japan | 4229918 | ⤷ Sign Up | |
| Mexico | 9706402 | EMULSIaN DE GAS ESTABILIZADA, QUE CONTIENE FOSFOLIPIDOS PARA AUMENTAR EL CONTRASTE DEL ULTRASONIDO. (STABILIZED GAS EMULSION CONTAINING PHOSPHOLIPID FOR ULTRASOUND CONTRAST ENHANCEMENT.) | ⤷ Sign Up |
| European Patent Office | 0812214 | ⤷ Sign Up | |
| Poland | 321952 | ⤷ Sign Up | |
| Australia | 8933898 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
